🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,257 results for “First” Clear

  1. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  2. A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia

    The George Institute

    Relapse/ refractory acute Leukemia

    phase 1 other active

    1 trial

  3. A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors

    Samsung Bioepis NL B.V.

    advanced refractory solid tumors

    phase 1 other active

    1 trial

  4. A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

    NovoThirteen

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  5. A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

    Chongqing Precision Biotech Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  6. A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

    Sanofi-aventis Healthcare Pty Ltd

    Osteoarthritis

    phase 1 other active

    1 trial

  7. A first-in-human study to learn about how safe BAY 3375968 is, how it moves into, through, and out of the body, and to find its best dose when given alone or with pembrolizumab in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  8. A first-in-human study to learn about how safe BAY 3620122 is, how much of it gets absorbed in the blood, and how it affects the body of healthy participants

    Bayer AG

    Vasodilatory shock

    phase 1 other active

    1 trial

  9. A first-in-human study to learn about how safe the study drug is in healthy participants

    Bayer AG

    Cardiac arrhythmia

    phase 1 other active

    1 trial

  10. A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial

  11. A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, and how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial

  12. A first-in-human trial to evaluate safety, tolerability, and pharmacokinetics of single and multiple oral doses of Debio 1453P in healthy adults

    Alphapharm Pty Ltd

    Sexual Transmitted Infection (STI)

    phase 1 other active

    1 trial

  13. A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.15205 after single and repeated oral ascending doses, including the BP1.15205 effect on cardiac repolarization, as well as an exploratory assessment of the food effect on the pharmacokinetics of BP1.15205 in healthy participants

    Bioprojet Pharma

    Narcolepsy

    phase 1 other active

    1 trial

  14. A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part

    Novartis Pharmaceuticals

    Heart failure (HF)

    phase 1 other active

    1 trial

  15. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  16. A phase 1, randomized, double-blind, single-center, placebo-controlled first-in-human trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD7007 in healthy participants

    Lacuna Pharma Pty Ltd

    Complement-mediated diseases

    phase 1 other active

    1 trial

  17. A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine safety, tolerability, and pharmacokinetics of GRT7040 in healthy volunteers

    Gruenenthal GmbH

    Treatment of pain

    phase 1 other active

    1 trial

  18. A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  19. A-CAR028

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 1 mab active

    1 trial

  20. AFN50 injection

    The First People's Hospital of Lianyungang

    Autoimmune Diseases

    phase 1 mab active

    1 trial

  21. ATHENA CAR-T

    The First People's Hospital of Lianyungang

    Lupus Erythematosus, Systemic

    phase 1 mab active

    1 trial

  22. Adebrelimab

    The First People's Hospital of Lianyungang

    Biliary Tract Malignancies

    phase 1 small molecule active

    1 trial

  23. Akk Gut Bacteria Supplement

    The First People's Hospital of Lianyungang

    Premature Ovarian Failure (POF)

    phase 1 other active

    1 trial

  24. All-trans retinoic acid

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources